Advanced Enzyme Technologies Limited has approved a buyback of its fully paid-up equity shares through the open market route, aiming to return surplus cash to shareholders and enhance return on equity. The Board of Directors, meeting on August 8, 2026, authorized a maximum buyback size of ₹697,000,000 (Rupees Six Hundred Ninety Seven Million only) at a price not exceeding ₹500 per equity share. This move represents a significant premium over recent trading prices and is funded entirely from free reserves and internal accruals, with no borrowed funds utilized.

Buyback Offer Parameters

The buyback targets up to 1,394,000 equity shares, which constitutes approximately 1.24% of the total paid-up equity share capital as of August 8, 2026. The transaction adheres to statutory limits, representing 9.99% of the aggregate of total paid-up share capital and free reserves based on audited standalone financial statements as at March 31, 2026.

The company must utilize at least 75% of the Maximum Buyback Size, i.e., ₹522,750,000. Furthermore, at least 40% of the Buyback Size, i.e., ₹278,800,000, must be deployed within the initial half of the Offer Period. The buyback offer is expected to open on or before August 14, 2026, and close no later than November 20, 2026, being sixty-six Working Days from the opening date.

Premium and Market Context

The Maximum Buyback Price of ₹500 carries a substantial premium over recent market benchmarks. On August 8, 2026, the closing market price was ₹324.40 on BSE and ₹324.35 on NSE.

This premium reflects management’s confidence in the intrinsic value of the shares and serves as a strong signal to investors regarding the company’s financial health and future prospects.

Capital Structure Impact

If the full Maximum Buyback Size is utilized at the Maximum Buyback Price, the issued, subscribed, and paid-up capital will reduce from 111,976,150 shares to 110,582,150 shares. Promoters and persons in control are excluded from participating in the buyback; their shares will remain frozen at the ISIN level from August 8, 2026, until the buyback closes.

Financial Health and Rationale

The buyback is underpinned by strong financial performance. For Q1 FY27 (ended June 30, 2026), the company reported Revenue from Operations of ₹1,158.57 million and Profit After Tax of ₹223.46 million. In FY2026, Revenue from Operations stood at ₹4,527.66 million with a PAT of ₹1,318.06 million.

The Board confirmed that the company has no subsisting defaults in repayment of deposits, debentures, preference shares, dividends, or term loans. A cash escrow of ₹174,250,000 (25% of Maximum Buyback Size) has been deposited with HDFC Bank Limited. Emkay Global Financial Services Limited serves as the Manager to the Buyback, while MUFG Intime India Private Limited is the Registrar. The process complies with Regulation 5(vii) of the SEBI (Buy-back of Securities) Regulations, 2018, and relevant provisions of the Companies Act, 2013.

Advanced Enzyme Technologies Limited reported a consolidated net profit of ₹386 million for the quarter ended June 30, 2026 (Q1FY27), a 5% decline from ₹404 million in the corresponding period of the previous year. While revenue from operations grew by 2% to ₹1,898 million, profitability was impacted by a 10% year-on-year drop in EBITDA to ₹510 million, compressing the EBITDA margin to 27% from 30%. The results reflect mixed segmental performance, with growth in Bio-Processing and Specialized Manufacturing offsetting declines in Human and Animal Nutrition.

Consolidated Financial Performance

The company’s total income stood at approximately ₹2,028 million, supported by other income that contributed to the bottom line despite operational headwinds. Profit before tax decreased by 3% to ₹535 million from ₹549 million in Q1FY26. After accounting for tax expenses, the net profit attributable to shareholders was ₹370.93 million, resulting in basic and diluted earnings per share (EPS) of ₹3.31, down from ₹3.57 in the prior year quarter.

Financial costs remained low at ₹6 million, unchanged from ₹8 million in Q1FY26. Depreciation and amortization charges increased slightly to ₹99 million from ₹96 million in the previous year’s quarter.

Segmental and Geographical Breakdown

Revenue performance varied significantly across business segments. The Human Nutrition segment, which constitutes the largest share of revenue, declined by 7% year-on-year to ₹1,139 million, primarily due to lower sales in the Pharma/API business. Animal Nutrition also saw a slight contraction of 3%, dropping to ₹252 million from ₹260 million.

In contrast, the Bio-Processing segment delivered robust growth, rising 30% to ₹306 million. This was largely driven by the Food business, which grew 51% year-on-year to ₹263 million. The Specialized Manufacturing segment also performed well, increasing by 41% to ₹200 million.

Geographically, international sales accounted for 51% of total revenue, up from 47% in Q1FY26. International revenue rose 9% to ₹961 million, fueled by strong growth in Europe (44%) and Asia excluding India (37%). Domestic sales constituted 49% of revenue, declining 4% to ₹937 million.

What the Numbers Show

The divergence between revenue growth and margin contraction highlights structural shifts in the company’s product mix. While high-growth segments like Bio-Processing and Specialized Manufacturing expanded their contribution, they were not sufficient to fully offset the volume decline in the higher-revenue Human Nutrition segment. The 300 basis point compression in EBITDA margin suggests potential pricing pressures or higher input costs in core segments, warranting close monitoring in subsequent quarters as management focuses on expanding its probiotics portfolio and B2C presence through its new brand, Wellfa.